Quantitative detection method of levofloxacin in plasma

Abstract

The invention belongs to the field of detection technology of levofloxacin, and discloses a quantitative detection method of levofloxacin in plasma. The method comprises the following steps: weighinglevofloxacin reference substance and levofloxacin-d8, diluting the levofloxacin reference substance and the levofloxacin-d8 with methanol and a methanol aqueous solution to obtain a series of levofloxacin working solutions and internal standard working solutions; pretreating a plasma sample by using the internal standard working solutions and a methanol precipitant, and performing LC-MS / MS analysis; preparing a series of correction guide samples and accompanying quality control samples by using blank plasma and the series of levofloxacin working solutions, then respectively performing LC-MS / MSmeasurement, using a chromatographic peak area ratio of the levofloxacin and the internal standard levofloxacin-d8 as a vertical coordinate, using the concentration of levofloxacin in the plasma as an abscissa to make a standard curve, and calculating the concentration of the levofloxacin in the plasma sample. The quantitative detection method disclosed by the invention has the advantages that measurement is performed via precipitation pretreatment and an LC-MS / MS mass spectrometer, so that the operation is quick and simple, the separation effect is good, the qualitative determination is accurate, and the detection sensitivity is high.

Description

technical field [0001] The invention belongs to the technical field of levofloxacin detection, and in particular relates to a quantitative detection method for levofloxacin in blood plasma. Background technique [0002] Levofloxacin is the third generation of fluoroquinolones. It has a broad-spectrum bactericidal effect on Gram-positive bacteria, and has a strong and long-lasting antibacterial effect. It is suitable for the treatment of respiratory system, urinary system, Digestive system, skin and soft tissue infection, etc. The dextroisomer of ofloxacin has almost no antibacterial effect, and its toxicity is greater than that of the levoisomer. Therefore, levofloxacin has been widely used clinically and has been approved by the US FDA for the treatment of hospital-acquired pneumonia. Levofloxacin was successfully developed by Japan's Daiichi Pharmaceutical Co., Ltd. in 1994 and launched in Japan. It was approved by the FDA in 1996. It is clinically used to treat mild and...

AI Technical Summary

Problems solved by technology

However, the current detection method of levofloxacin has defects such as long detection time, unstable detection quality and small injection volume, which seriously affects the progress of the consistency evaluation of levofloxacin and the pharmacokinetic characteristics of levofloxacin in human plasma, and increases the difficulty and difficulty of its administration. Follow-up research difficulty

Images